Research Phase Postdoctoral Fellows
Mitchell Yu, PhD
2023-2025
Mitchell Yu received his PhD in physics from York University, Canada, in 2022, where he studied neutrino physics. Transitioning from the field of high-energy physics to medical physics, Dr. Yu completed the CAMPEP-accredited Medical Physics Certificate Program at Columbia University. Dr. Yu joined the 2+2 hybrid MSK Medical Physics Residency Program in 2023 and is contributing to developing the next-generation fast gated Cone-Beam CT.
Gunjan Kayal, PhD
2024-2026
Gunjan Kayal earned her PhD in Medical Physics from Université Toulouse III - Paul Sabatier, INSERM, France, and Belgian Nuclear Research Centre SCKCEN, Belgium. Her doctoral research focused on dosimetric calculations and the standardization of dosimetry protocols in molecular radiotherapy using GATE Monte Carlo simulations. Her primary research interests include quantitative imaging and dosimetry in radiopharmaceutical therapy.
In 2024, Gunjan began her hybrid 2+2 medical physics residency program. In the first two years, she is working with Dr. Adam Kesner on developing MIRDsoft tools for managing dosimetry data in nuclear medicine, computed tomography, and hybrid imaging. The following two years will involve clinical rotations in diagnostic imaging, nuclear medicine, radiation safety, small animal imaging, and radiation oncology.
Clinical Phase Residents
Alexandre Franca Velo, PhD
2024–2026
Alexandre França Velo obtained his PhD in Nuclear Technology from the University of São Paulo, Brazil, specializing in image reconstruction and Monte Carlo simulation. Dr. Velo joined Yale University in 2020 as a postdoctoral researcher associate in the Department of Radiology and Biomedical Imaging, where he primarily focused on scatter correction techniques and Monte Carlo simulations.
Subsequently, in 2022, he joined the hybrid 2+2 program at Memorial Sloan Kettering Cancer Center under the supervision of Dr. John Humm. His research involves advanced imaging techniques that use PET imaging to determine intra-tumor uptake and distribution of the radiolabeled drugs. He worked on theranostic technics along with Monte Carlo simulation to estimate radiation absorbed dose and DNA strand breaks.
He begins his clinical training in summer 2024.
Harry Marquis, PhD
2024–2026
Harry Marquis joined the hybrid research and medical physics residency program at Memorial Sloan Kettering Cancer Center in 2022.
Dr. Marquis completed his PhD at the University of Sydney, where his research focused on developing a dosimetry platform for theranostic agents. His key research interests are in quantitative PET and SPECT imaging, diagnostic medical imaging, theranostics and radionuclide therapy dosimetry.
Harry worked with Dr. Adam Kesner as a postdoctoral researcher focusing on the development of MIRDsoft applications for deriving, reporting, and managing dosimetry data in nuclear medicine.
He begins his clinical training in summer 2024.